Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
A New Frontier in Myeloma: mRNA-2808 Targets BCMA, GPRC5D & FcRH5 with One Therapy | ASCO 2026
HealthTreeDescription
At ASCO 2026, Dr. Hans Lee presented the first clinical study of mRNA-2808, an innovative mRNA-based therapy for relapsed/refractory multiple myeloma. Unlike conventional bispecific antibodies, mRNA-2808 delivers genetic instructions that enable the body to produce three T-cell engagers targeting BCMA, GPRC5D, and FcRH5. This novel strategy aims to overcome tumor heterogeneity, reduce treatment resistance, and improve immune-mediated killing of myeloma cells. Learn about the study design, patient eligibility, safety findings, and why this platform could represent a new direction for immunotherapy in multiple myeloma.
If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu
For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.